Pediatric Oncology | Specialty

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

Hispanic Ethnicity Associated With Poorer OS in Pediatric Neuroblastoma

May 26th 2022

Non-White Hispanic children and those with public insurance care in a clinical trial for high-risk neuroblastoma had inferior overall survival rates compared with other children.

Transplants Are in His Blood: Richard J. O'Reilly Is a Giant of Cancer Care in Pediatric Cancer

April 4th 2022

“I can’t conceive of anything worse than being in a situation where you can’t ask, ‘How do we get better?’ ”

FDA Approval Sought for Ibrutinib in Pediatric Chronic Graft-Versus-Host Disease

February 28th 2022

A supplemental new drug application has been submitted to the FDA seeking the approval of ibrutinib for the treatment of pediatric and adolescent patients aged 1 year and older with chronic graft-vs-host disease following failure of 1 or more lines of systemic therapy.

Nearly 300 Novel Agents Currently in Development for Rare Cancers

February 24th 2022

New agents for rare cancers make up approximately 35% of drugs in the pipeline for all rare diseases, according to a report from the Pharmaceutical Research and Manufacturers of America.

Breaking New Ground in Childhood Cancer

February 9th 2022

Accelerating progress in childhood cancer faces three main obstacles: funding, drugs, and family support.

NCCN Voices a Call to Action Against Health Care Inequity on World Cancer Day

February 8th 2022

The National Comprehensive Cancer Network is one of many organizations that is taking a stand against inequity in health care by aligning themselves with the new 3-year campaign, entitled “Close the Care Gap,” led by the Union for International Cancer Control.

Biden-Harris Administration Revives Cancer Moonshot Program

February 3rd 2022

The Biden-Harris administration has announced a plan to restart the Cancer Moonshot initiative, which President Joe Biden first launched as vice president of the Obama administration in 2016.

FDA Grants Rare Pediatric Disease Designation to Novel Radiopharmaceutical for Osteosarcoma

February 2nd 2022

The FDA has granted a rare pediatric disease designation to the bone-targeting radiopharmaceutical, Samarium-153-DOTMP, for use as a potential therapeutic option for patients with osteosarcoma.

Activating the Immune System Could be Key to Treating Pediatric Neuroblastoma

January 11th 2022

Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma, and the humanized anti-disialoganglioside monoclonal antibody hu14.18K322A could provide a breakthrough for children with high-risk disease.

Finding Focus in Fellowship

December 26th 2021

Leslie S. Kersun, MD, MSCE, MSEd, discusses finding the right fellowship program; the challenge of balancing research, patient care, and education as a trainee; and finding one’s focus during fellowship.

Yale Cancer Center Researchers Show Receptor Structure Reveals New Targets for Cancer Treatment

December 10th 2021

Two new studies by Yale Cancer Center reveal the structure of the molecule known as anaplastic lymphoma kinase, which is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors.

FDA Approval Sought for Betibeglogene Autotemcel for Transfusion-Dependent Beta-Thalassemia

September 22nd 2021

A rolling submission of a biologic license application to the FDA has been completed for betibeglogene autotemcel for use in adult, adolescent, and pediatric patients with beta-thalassemia who require regular red blood cell transfusions, across all genotypes.

Lee-Kim on Fostering a Fulfilling Fellowship in Oncology

June 28th 2021

Dr. Lee-Kim discusses her path into treating pediatric patients with cancer, key lessons that can be learned during fellowship, and tips on managing finances and burnout during a pediatric oncology fellowship program.

NDA Resubmitted to FDA for Pedmark in Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors

June 1st 2021

The new drug application seeking the approval of a unique formulation of sodium thiosulfate for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmetastatic solid tumors has been resubmitted to the FDA.

To Advance as a Fellow, Be Open to the Unexpected

May 22nd 2021

YoungNa Lee-Kim, MD, shares advice on how to advance as an oncology fellow.

Dr. Yohe on the Potential to Target RAS Mutations in Pediatric Cancers

May 17th 2021

Marielle E. Yohe, MD, PhD, discusses the potential utility of targeting RAS mutations in pediatric cancers.

NKT Cells Co-Expressing GD2-CAR, IL-15 Can Induce Complete Remissions in Pediatric Neuroblastoma

May 15th 2021

Natural killer T cells that co-express GD2-CAR and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.

Yale Cancer Center Study Shows Cognitive Impairment for Survivors of Many Pediatric Cancers

May 14th 2021

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income.

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

May 10th 2021

Sara M. Federico, MD, discusses the diagnosis and presentation of neuroblastoma, the role of multidisciplinary care, and novel therapies that could significantly affect the treatment paradigm for this malignancy.

FDA Grants Priority Review to SH-111 for Pediatric T-Cell Leukemia

April 23rd 2021

The FDA has granted a priority review designation to SH-111, a sterile injectable therapy, for the treatment of pediatric patients with T-cell leukemia.